Stuart Arbuckle
Equibles does not estimate personal net worth.
About Stuart Arbuckle
Earlier roles on record: COO at Vertex Pharmaceuticals Inc (VRTX) until July 1, 2025. The proxy statement of Vertex Pharmaceuticals Inc reports total compensation of $9,996,347 for Stuart Arbuckle in fiscal 2025, including a base salary of $521,486. Disclosed compensation is on record for 9 fiscal years. Stuart Arbuckle has spoken on 14 earnings calls across 1 company, most recently for Vertex Pharmaceuticals Inc on February 10, 2025. The companies whose calls Stuart Arbuckle spoke on are classified in the Healthcare sector.
Stuart Arbuckle on recent calls
“While I admit to having very mixed emotions about retiring from Vertex in July, I know that the timing is right from both a professional and personal standpoint.”
“I’ll begin by discussing CF and then provide some highlights of the ongoing CASGEVY launch and the outlook for suzetrigine in acute pain.”
“I'll first discuss CF then provide some highlights of the ongoing CASGEVI launch and the outlook for Suzetrigine in acute pain.”
“I'll first discuss CF, and then as we're entering a new era of commercial diversification, provide some highlights of the ongoing CASGEVY launch and the outlook for suzetrigine in acute pain.”
“With the recent approvals of CASGEVY in sickle cell disease and transfusion-dependent thalassemia in multiple countries and the recent positive results in our pivotal trials for VX-548 in acute pain and for the vanzacaftor triple combination in CF, we are well and truly entering a new era of commercial diversification.”
Affiliation history
-
Vertex Pharmaceuticals Inc (VRTX)
Proxy statement
Start not stated–2021-04-08
Last confirmed by a filing; no departure on record
-
Start not stated–2025-07-01
Company network
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Vertex Pharmaceuticals Inc (VRTX) | Former EVP & Chief Operating Officer | $521,486 | $9,996,347 |
| 2024 | Vertex Pharmaceuticals Inc (VRTX) | EVP & Chief Operating Officer | $941,154 | $9,383,463 |
| 2023 | Vertex Pharmaceuticals Inc (VRTX) | EVP & Chief Operating Officer | $900,000 | $8,998,949 |
| 2022 | Vertex Pharmaceuticals Inc (VRTX) | EVP & Chief Operating Officer | $900,000 | $14,999,106 |
| 2021 | Vertex Pharmaceuticals Inc (VRTX) | EVP & Chief Operating Officer | $842,308 | $7,810,141 |
| 2020 | Vertex Pharmaceuticals Inc (VRTX) | EVP & Chief Operating Officer | $830,769 | $7,282,978 |
| 2019 | Vertex Pharmaceuticals Inc (VRTX) | EVP & Chief Operating Officer | $770,962 | $6,859,533 |
| 2018 | Vertex Pharmaceuticals Inc (VRTX) | EVP & Chief Commercial and Operations Officer | $721,923 | $5,347,092 |
| 2017 | Vertex Pharmaceuticals Inc (VRTX) | EVP & Chief Commercial Officer | $700,000 | $4,400,633 |